Donald Trump's pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. The report said that included up to $39.1 million worth of stock held in companies that benefited from exemptions to Medicare's drug price negotiation program, which came through a provision in Republicans' 2025 tax and spending law. Trump's financial disclosures showed his investment portfolio bought $2.55 million in shares of pharmaceutical companies benefiting from the exemptions from Republican / Jeff Van Drew passed Bills.